Ann: Commencement of Larger Animal Studies for Lead Program, page-6

So now we are 12 months behind the milestones advised at the 2020 AGM and the 20 Oct 2020 Presentation for the equity raising

I get as annoyed as anyone at slipping timelines but I’m not sure why you think that the program has slipped back by 12 months since October/November last year.

This is from the announcement today

Larger animal studies for VP-001 have commenced on schedule in Q2 2021 and will continue throughout Q3 2021

Subsequent to the GLP studies, PYC anticipates submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in mid-2022 before commencing clinical development


And these were the milestones advised in the equity raising presentation and at the AGM last year




To me, it looks like the lead program is roughly a quarter behind. Of course, we are yet to see if a mid-2022 IND submission transpires.